Fluticasone Furoate 相關新聞
Fluticasone Furoate 目前有 1 則相關新聞報導,預測適應症 20 個。
本頁整合 Fluticasone Furoate 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
- 原適應症:Asthma Indication Revinty Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and...
- 證據等級:L1
- 預測適應症(20 個):
- atopic eczema(100.0%)
- allergic asthma(100.0%)
- intrinsic asthma(100.0%)
- bronchitis(99.9%)
- asthma(99.9%)
- 2-hydroxyethyl methacrylate sensitization(99.9%)
- dermatitis, atopic(99.8%)
- contact dermatitis(99.5%)
- asthma-related traits, susceptibility to(99.4%)
- occupational dermatitis(99.3%)
- phototoxic dermatitis(99.1%)
- obstructive lung disease(98.9%)
- polyp of vocal cord(98.9%)
- polyp of middle ear(98.9%)
- fibroepithelial polyp(98.8%)
- seborrheic dermatitis(98.8%)
- neoplastic polyp(98.8%)
- atopic dermatitis(98.8%)
- polyp of vulva(98.8%)
- polyp of frontal sinus(98.8%)
相關新聞(1 則)
Aktualisierte S2k-Leitlinie COPD 2026: Individualisierte Pharmakotherapie im Fokus - Gelbe Liste
2026-04-27 copd
來源:Gelbe Liste
免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。